BMRN analyst estimates
BioMarin (BMRN) analyst ratings, the average price target and its range, and every firm's latest call.
BMRN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | BioMarin price target lowered to $122 from $124 at Morgan Stanley | $122.00 |
| Oct 14, 2026 | Barclays | BioMarin price target raised to $114 from $111 at Barclays | $114.00 |
| Sep 15, 2026 | BMO Capital | BioMarin price target lowered to $97 from $98 at BMO Capital | $97.00 |
| Sep 1, 2026 | Piper Sandler | BioMarin price target raised to $90 from $88 at Piper Sandler | $90.00 |
| Sep 1, 2026 | Cantor Fitzgerald | BioMarin price target raised to $86 from $85 at Cantor Fitzgerald | $86.00 |
| Aug 31, 2026 | Raymond James | BioMarin price target raised to $109 from $105 at Raymond James | $109.00 |
| Aug 31, 2026 | Jefferies | BioMarin price target raised to $105 from $104 at Jefferies | $105.00 |
| Aug 26, 2026 | UBS | Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings' | $88.00 |
| Aug 18, 2026 | H.C. Wainwright | BioMarin price target lowered to $59 from $60 at H.C. Wainwright | $59.00 |
| Aug 18, 2026 | BMO Capital | BioMarin initiated with an Outperform at BMO Capital | $98.00 |
| Aug 17, 2026 | Barclays | BioMarin price target raised to $111 from $105 at Barclays | $111.00 |
| Aug 17, 2026 | Piper Sandler | BioMarin price target raised to $88 from $82 at Piper Sandler | $88.00 |
| Aug 10, 2026 | Canaccord Genuity | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord | $114.00 |
| Aug 7, 2026 | Morgan Stanley | BioMarin price target raised to $124 from $119 at Morgan Stanley | $124.00 |
| Aug 7, 2026 | Raymond James | BioMarin price target raised to $105 from $100 at Raymond James | $105.00 |
- 21 firms rate BMRN: 16 buy, 5 hold, 0 sell.
- The average price target is $98.40 from 10 analysts, from $59.00 to $122.00.
Updated 2026-11-02 23:11 UTC